ABBV vs. BIO: AbbVie vs. Bio-Rad Laboratories Stock Comparison

November 11, 2026

How do AbbVie (ABBV) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Bio-Rad Laboratories (BIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while BIO is classified in Life Sciences Tools & Services.

Company profile comparison for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Profile Item	ABBV	BIO
Name	AbbVie Inc.	Bio-Rad Laboratories Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	514.92 billion USD	10.26 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	February 27, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

BIO

GSPC

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Bio-Rad Laboratories (BIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Bio-Rad Laboratories (BIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
Total Return (1Y)	37.33%	28.31%
Total Return (3Y, Annualized)	32.74%	8.52%
Total Return (5Y, Annualized)	24.73%	-11.74%

Risk Profile

Drawdown History

ABBV

BIO

GSPC

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Bio-Rad Laboratories (BIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
Volatility (1Y, Annualized)	25.65%	36.50%
Beta (5Y)	0.21	1.03
Max Drawdown (5Y)	-21.92%	-72.24%
Avg. Volume (3M)	4.76M	250.78K

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and BIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
Sharpe Ratio (1Y)	1.29	0.66
Sortino Ratio (1Y)	2.02	0.98

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Bio-Rad Laboratories (BIO) earns 14.27% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max: 109.18%
BIO: 14.27%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): ABBV does not report ROE, so it has no value marker; BIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO: 39.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AbbVie (ABBV) at 39.59% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.82%

Max: 83.12%
Q3: 14.77%
BIO: 11.82%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
ROE (TTM)	--	14.27%
ROA (TTM)	10.74%	1.50%
Net Margin (TTM)	15.67%	39.45%
Operating Margin (TTM)	39.59%	11.82%
Gross Margin (TTM)	73.72%	52.19%

Growth

Revenue Growth

Both AbbVie (ABBV) at 8.57% and Bio-Rad Laboratories (BIO) at 0.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
Revenue Growth (YoY)	8.57%	0.65%
Revenue Growth (3Y CAGR)	1.75%	-2.68%
EPS Growth (YoY)	-0.84%	--
EPS Growth (3Y CAGR)	-29.03%	--

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max: 25.13
Q3: 12.13
Median: 5.52
BIO: 3.18
Q1: 2.47
Min: 0.10

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Bio-Rad Laboratories (BIO) carries debt-to-equity ratio of 0.18 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max: 1.42
Q3: 0.65
BIO: 0.18
Median: 0.15
Q1: 0.02
Min: 0.00

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): ABBV does not report debt-to-equity ratio, so it has no value marker; BIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
Current Ratio (MRQ)	0.87	3.18
Debt / Equity (MRQ)	--	0.18
Net Debt / EBITDA	2.21	-0.73

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
Dividend Yield (TTM)	2.40%	0.00%
Dividend Payout Ratio (TTM)	117.35%	0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while AbbVie (ABBV) at 50.05 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.14

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
BIO: 10.14
Min: 0.07

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.80 and Bio-Rad Laboratories (BIO) at 3.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.96

Max: 58.18
Q3: 25.77
Median: 7.30
BIO: 3.96
Q1: 3.01
Min: 0.01

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Bio-Rad Laboratories (BIO) reports 1.35, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BIO: 1.35
Min: -5.59

AbbVie (ABBV) vs. Bio-Rad Laboratories (BIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Bio-Rad Laboratories (BIO)
Metric	ABBV	BIO
P/E Ratio (TTM)	50.05	10.14
P/S Ratio (TTM)	7.80	3.96
P/B Ratio (MRQ)	-112.34	1.35
Free Cash Flow Yield (TTM)	3.44%	2.65%